ET Healthcare develops an automated immunodiagnostics solution.
ET Healthcare develops an automated immunodiagnostics solution designed to address comprehensive needs, including inflammation, cardiac function, fertility, infectious diseases, and tumors. Pylon, a product from ET Healthcare, is intended to bring immunoassay performance typically associated with central lab analyzers to the near-patient setting. This entails addressing specific near-patient testing requirements such as reduced facility requirements for space, plumbing, and electricity, as well as lower demand for human resources such as trained operators or staff numbers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 18, 2021 | Series G | $105M | 1 | — | — | Detail |
Sep 21, 2018 | Series C | $17.50M | 2 | Maison Capital | — | Detail |
May 1, 2017 | Series Unknown | $7M | 1 | Qiming Venture Partners | — | Detail |
Nov 11, 2015 | Series B | — | 4 | Qiming Venture Partners | — | Detail |
Mar 5, 2014 | Series A | — | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Maison Capital | Yes | Series C |
Qiming Venture Partners | — | Series G |
Legend Capital | — | Series B |
Matrix Partners China | — | Series B |